Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669901 · ClinicalTrials.gov registry record · NA
Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
A NA study, sponsored by University of New Mexico.
- Completed
- Registry status
- NA
- Development phase
- 395
- Enrollment target
NCT02669901: Completed NA study, sponsored by University of New Mexico.
NCT02669901 is a NA study that has completed, run by University of New Mexico. The registered enrollment target is 395 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02669901, a NA study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- NA
- Development phase
- 395 participants
- Enrollment target
Study Summary
The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional opioid overdose risk utilizing an evidence-based screening questionnaire.
Primary Outcome
The study participants received 2 naloxone kits at their initial visit. They were educated on how to recognize the signs and symptoms of an OD, the importance of calling 911, rescue breathing techniques, and staying with the person experiencing the OD until medical help has arrived. They were asked about their use of naloxone every 3 months, including the situation of the naloxone kits, dose, and to whom they used.
Interventions
- BEHAVIORAL Naloxone Auto-Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2020-08-20 |
| Phase | NA |
What the finished NCT02669901 record still lists
NCT02669901 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which Naloxone Auto-Injector is the first listed.
NCT02669901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02669901 about?
NCT02669901 is a clinical study titled "Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder". The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk factors for serious opioid...
What is the current status of trial NCT02669901?
This trial is currently completed. It is a NA study. The enrollment target is 395 participants. The study started on 2016-04-04. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT02669901?
The interventions under investigation include: Naloxone Auto-Injector (BEHAVIORAL).
Who is sponsoring clinical trial NCT02669901?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02669901's enrollment target sits among peer trials
395 268th of 2000 higher than 1,733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI